Last reviewed · How we verify
Dapagliflozin + Lobeglitazone
This combination reduces blood glucose by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys while simultaneously activating peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.
This combination reduces blood glucose by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys while simultaneously activating peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Dapagliflozin + Lobeglitazone |
|---|---|
| Also known as | Forxiga 10mg + Duvie 0.5mg |
| Sponsor | Seoul National University Bundang Hospital |
| Drug class | SGLT2 inhibitor + thiazolidinedione combination |
| Target | SGLT2 and PPAR-γ |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Dapagliflozin is an SGLT2 inhibitor that promotes urinary glucose excretion independent of insulin secretion. Lobeglitazone is a thiazolidinedione that enhances insulin sensitivity by activating PPAR-γ in adipose tissue and muscle. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Weight gain
- Fluid retention/edema
- Hypoglycemia
Key clinical trials
- Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors (PHASE4)
- Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety (PHASE4)
- Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: